Literature DB >> 23354982

Time-dependent propensity score and collider-stratification bias: an example of beta2-agonist use and the risk of coronary heart disease.

M Sanni Ali1, Rolf H H Groenwold, Wiebe R Pestman, Svetlana V Belitser, Arno W Hoes, A de Boer, Olaf H Klungel.   

Abstract

Stratification and conditioning on time-varying cofounders which are also intermediates can induce collider-stratification bias and adjust-away the (indirect) effect of exposure. Similar bias could be expected when one conditions on time-dependent PS. We explored collider-stratification and confounding bias due to conditioning or stratifying on time-dependent PS using a clinical example on the effect of inhaled short- and long-acting beta2-agonist use (SABA and LABA, respectively) on coronary heart disease (CHD). In an electronic general practice database we selected a cohort of patients with an indication for SABA and/or LABA use and ascertained potential confounders and SABA/LABA use per three month intervals. Hazard ratios (HR) were estimated using PS stratification as well as covariate adjustment and compared with those of Marginal Structural Models (MSMs) in both SABA and LABA use separately. In MSMs, censoring was accounted for by including inverse probability of censoring weights.The crude HR of CHD was 0.90 [95 % CI: 0.63, 1.28] and 1.55 [95 % CI: 1.06, 2.62] in SABA and LABA users respectively. When PS stratification, covariate adjustment using PS, and MSMs were used, the HRs were 1.09 [95 % CI: 0.74, 1.61], 1.07 [95 % CI: 0.72, 1.60], and 0.86 [95 % CI: 0.55, 1.34] for SABA, and 1.09 [95 % CI: 0.74, 1.62], 1.13 [95 % CI: 0.76, 1.67], 0.77 [95 % CI: 0.45, 1.33] for LABA, respectively. Results were similar for different PS methods, but higher than those of MSMs. When treatment and confounders vary during follow-up, conditioning or stratification on time-dependent PS could induce substantial collider-stratification or confounding bias; hence, other methods such as MSMs are recommended.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354982     DOI: 10.1007/s10654-013-9766-2

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  30 in total

1.  Quantifying biases in causal models: classical confounding vs collider-stratification bias.

Authors:  Sander Greenland
Journal:  Epidemiology       Date:  2003-05       Impact factor: 4.822

2.  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis.

Authors:  Shelley R Salpeter; Thomas M Ormiston; Edwin E Salpeter
Journal:  Chest       Date:  2004-06       Impact factor: 9.410

Review 3.  Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review.

Authors:  Baiju R Shah; Andreas Laupacis; Janet E Hux; Peter C Austin
Journal:  J Clin Epidemiol       Date:  2005-04-19       Impact factor: 6.437

4.  Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

Authors:  Tobias Kurth; Alexander M Walker; Robert J Glynn; K Arnold Chan; J Michael Gaziano; Klaus Berger; James M Robins
Journal:  Am J Epidemiol       Date:  2005-12-21       Impact factor: 4.897

5.  Systematic differences in treatment effect estimates between propensity score methods and logistic regression.

Authors:  Edwin P Martens; Wiebe R Pestman; Anthonius de Boer; Svetlana V Belitser; Olaf H Klungel
Journal:  Int J Epidemiol       Date:  2008-05-03       Impact factor: 7.196

6.  Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction.

Authors:  David H Au; J Randall Curtis; Nathan R Every; Mary B McDonell; Stephan D Fihn
Journal:  Chest       Date:  2002-03       Impact factor: 9.410

7.  Identifiability, exchangeability, and epidemiological confounding.

Authors:  S Greenland; J M Robins
Journal:  Int J Epidemiol       Date:  1986-09       Impact factor: 7.196

8.  The role of the c-statistic in variable selection for propensity score models.

Authors:  Daniel Westreich; Stephen R Cole; Michele Jonsson Funk; M Alan Brookhart; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-09       Impact factor: 2.890

9.  Balancing Treatment Comparisons in Longitudinal Studies.

Authors:  Sue M Marcus; Juned Siddique; Thomas R Ten Have; Robert D Gibbons; Elizabeth Stuart; Sharon-Lise T Normand
Journal:  Psychiatr Ann       Date:  2008-12-01

10.  Constructing inverse probability weights for marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

View more
  5 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  Performance of time-dependent propensity scores: a pharmacoepidemiology case study.

Authors:  Wayne A Ray; Qi Liu; Bryan E Shepherd
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-11-18       Impact factor: 2.890

Review 3.  The Obesity Paradox and Heart Failure: A Systematic Review of a Decade of Evidence.

Authors:  Emmanuel Aja Oga; Olabimpe Ruth Eseyin
Journal:  J Obes       Date:  2016-01-20

4.  Insomnia symptoms as a cause of type 2 diabetes Incidence: a 20 year cohort study.

Authors:  Michael J Green; Colin A Espie; Frank Popham; Tony Robertson; Michaela Benzeval
Journal:  BMC Psychiatry       Date:  2017-03-16       Impact factor: 3.630

Review 5.  Propensity Score Methods in Health Technology Assessment: Principles, Extended Applications, and Recent Advances.

Authors:  M Sanni Ali; Daniel Prieto-Alhambra; Luciane Cruz Lopes; Dandara Ramos; Nivea Bispo; Maria Y Ichihara; Julia M Pescarini; Elizabeth Williamson; Rosemeire L Fiaccone; Mauricio L Barreto; Liam Smeeth
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.